IN8bio (INAB)
(Delayed Data from NSDQ)
$1.04 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INAB 1.04 0.00(0.00%)
Will INAB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INAB
Here's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom Fisher
IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross
INAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know
Other News for INAB
Promising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platform
12 Health Care Stocks Moving In Friday's After-Market Session
ATUS, ATHE and GRFS among pre-market losers
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), PainReform (PRFX) and IN8bio (INAB)
Analysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON) and IN8bio (INAB)